Does the Osteoporosis Dose of Denosumab Really Cause Clinically Significant Hypocalcaemia in CKD 4 and 5
Journal Title: Journal of Advances in Medicine and Medical Research - Year 2014, Vol 4, Issue 2
Abstract
Denosumab is a potent novel antiresorptive agent for treatment of osteoporosis with unique mechanism of action . It is a fully human monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL) that blocks its binding to RANK, inhibiting the development and activity of osteoclasts, decreasing bone resorption, and increasing bone density. Initially denosumab appeared particularly promising for patients with advanced stages of renal failure but over the past two years several publications questioned that, reporting adverse effects and especially severe hypocalcaemia. Aim of the Study: to investigate further the effect of the osteoporosis dose of denosumab on serum calcium levels in patients with CKD 4 and CKD 5. Methods: This retrospective outpatient study included 17 females with CKD 4 and 5 who received a single or a multiple (at 6 months intervals) 60-mg subcutaneous dose of denosumab. Adjusted serum Calcium was measured prior to the dose and at various points of time after that. Results: Only two of the subjects developed clinically significant hypocalcaemia. Both of them were clearly inadequately supplemented with calcium and vitamin D. Conclusion: The results from the current study along with a critical analysis of the previous publications reveal that the vast majority of the previous reports were based on inadequately supplemented with calcium and vitamin D patients and that severe hypocalcaemia is unlikely in appropriately supplemented subjects, especially in the CKD 4 subgroup. However, due to the scarcity of data further research is warranted, especially in the CKD 5 subgroup. In the mean time more cautious approach rather than a blanket ban on denosumab appears to be the most appropriate policy in these two populations.
Authors and Affiliations
Petko Ivanov
Keywords
Related Articles
- EP ID EP348497
- DOI 10.9734/BJMMR/2014/6300
- Views 73
- Downloads 0
Phantom Human Chorionic Gonadotropin in an End Stage Renal Disease Case
Aims: Gestation is very difficult in women with end stage renal disease (ESRD). In addition, human chorionic gonadotropin (HCG) may be increased in Non-pregnant women with ESRD. Therefore, elevated HCG levels in ESRD pat...
Prevalence and Determinants of Poor Sleep Quality among Myanmar Migrant Workers in Malaysia: A Cross-sectional Study
Background: Sleep quality is an important determinant of health; so much so that the socio-economic and healthcare burden of poor sleep quality is alarming. In Malaysia, there is a shortage of sleep-quality studies condu...
Does the Osteoporosis Dose of Denosumab Really Cause Clinically Significant Hypocalcaemia in CKD 4 and 5
Denosumab is a potent novel antiresorptive agent for treatment of osteoporosis with unique mechanism of action . It is a fully human monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL) that...
Radiologic Study of Ischiopubic Index of Urhobos and Itsekiris of Nigeria
The study was designed to determine and compare the pubic length, ischial length and ischiopubic indices amongst Urhobos and Itsekiris. The parameters were measured from radiographs obtained from the Radiology department...
A Rare Cause of Recurrent Epistaxis: Lobular Capillary Haemangioma
Nasal lobular capillary haemangiomata are rare benign nasal tumours of vascular origin and unknown etiology. They tend to occur in both sexes depending on the age group. They usually present with unilateral nasal obstruc...